Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Safety and Immunogenicity of the Therapeutic Vaccine TG1050 in Chronic Hepatitis B Patients: A Phase 1b Placebo-Controlled Trial.

Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, Leroy V, Ma M, Wedemeyer H, Lohse AW, Thimme R, Lugardon K, Martin P, Bastien B, Sansas B, Adda N, Halluard C, Bendjama K, Brandely M, Inchauspé G.

Hum Vaccin Immunother. 2019 Aug 2. doi: 10.1080/21645515.2019.1651141. [Epub ahead of print]

PMID:
31373537
2.

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.

Leung-Theung-Long S, Coupet CA, Gouanvic M, Schmitt D, Ray A, Hoffmann C, Schultz H, Tyagi S, Soni H, Converse PJ, Arias L, Kleinpeter P, Sansas B, Mdluli K, Vilaplana C, Cardona PJ, Nuermberger E, Marchand JB, Silvestre N, Inchauspé G.

PLoS One. 2018 May 2;13(5):e0196815. doi: 10.1371/journal.pone.0196815. eCollection 2018.

3.

A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model.

Kratzer R, Sansas B, Lélu K, Evlachev A, Schmitt D, Silvestre N, Inchauspé G, Martin P.

Hum Vaccin Immunother. 2018 Jun 3;14(6):1417-1422. doi: 10.1080/21645515.2018.1433970. Epub 2018 Feb 22.

4.

Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients.

Huang D, Sansas B, Jiang JH, Gong QM, Jin GD, Calais V, Yu DM, Zhu MY, Wei D, Zhang DH, Inchauspé G, Zhang XX, Zhu R.

J Viral Hepat. 2017 Nov;24 Suppl 1:66-74. doi: 10.1111/jvh.12791.

PMID:
29082648
5.

T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates.

Rollier CS, Verschoor EJ, Verstrepen BE, Drexhage JA, Paranhos-Baccala G, Liljeström P, Sutter G, Arribillaga L, Lasarte JJ, Bartosch B, Cosset FL, Inchauspe G, Heeney JL.

Gene Ther. 2016 Oct;23(10):753-759. doi: 10.1038/gt.2016.55. Epub 2016 Jul 14.

PMID:
27416077
6.

A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates.

Leung-Theung-Long S, Gouanvic M, Coupet CA, Ray A, Tupin E, Silvestre N, Marchand JB, Schmitt D, Hoffmann C, Klein M, Seegren P, Huaman MC, Cristillo AD, Inchauspé G.

PLoS One. 2015 Nov 24;10(11):e0143552. doi: 10.1371/journal.pone.0143552. eCollection 2015.

7.

Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.

Godon O, Evlachev A, Bourgine M, Meritet JF, Martin P, Inchauspe G, Michel ML.

Vaccine. 2015 Aug 26;33(36):4548-53. doi: 10.1016/j.vaccine.2015.07.020. Epub 2015 Jul 23.

PMID:
26209840
8.

The sero-prevalence of anti-adenovirus 5 neutralizing antibodies is independent of a chronic hepatitis B carrier state in China.

Huang D, Hennequi M, Elvachev A, Menguy T, Silvestre N, Yu D, Han Y, Inchauspé G, Zhang X, Zhu R.

Arch Virol. 2015 Apr;160(4):1125-30. doi: 10.1007/s00705-015-2333-2. Epub 2015 Jan 24.

9.

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.

Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, Kratzer R, Lelu-Santolaria K, Evlachev A, Meritet JF, Schlesinger Y, Villeval D, Strub JM, Van Dorsselaer A, Marchand JB, Geist M, Brandely R, Findeli A, Boukhebza H, Menguy T, Silvestre N, Michel ML, Inchauspé G.

Gut. 2015 Dec;64(12):1961-71. doi: 10.1136/gutjnl-2014-308041. Epub 2014 Nov 26.

10.

Comparative analysis of immunization schedules using a novel adenovirus-based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.

Boukhebza H, Dubois C, Koerper V, Evlachev A, Schlesinger Y, Menguy T, Silvestre N, Riedl P, Inchauspé G, Martin P.

Vaccine. 2014 May 30;32(26):3256-63. doi: 10.1016/j.vaccine.2014.03.089. Epub 2014 Apr 13.

PMID:
24726690
11.

Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.

Di Bisceglie AM, Janczweska-Kazek E, Habersetzer F, Mazur W, Stanciu C, Carreno V, Tanasescu C, Flisiak R, Romero-Gomez M, Fich A, Bataille V, Toh ML, Hennequi M, Zerr P, Honnet G, Inchauspé G, Agathon D, Limacher JM, Wedemeyer H.

Gastroenterology. 2014 Jul;147(1):119-131.e3. doi: 10.1053/j.gastro.2014.03.007. Epub 2014 Mar 18.

PMID:
24657484
12.

A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.

Fournillier A, Frelin L, Jacquier E, Ahlén G, Brass A, Gerossier E, Holmström F, Broderick KE, Sardesai NY, Bonnefoy JY, Inchauspé G, Sällberg M.

J Infect Dis. 2013 Sep;208(6):1008-19. doi: 10.1093/infdis/jit267. Epub 2013 Jun 17.

13.

Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.

Boukhebza H, Bellon N, Limacher JM, Inchauspé G.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1746-57. doi: 10.4161/hv.21689. Epub 2012 Aug 16. Review.

14.

A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C.

Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, Feray C, Baumert TF, Bronowicki JP, Doffoël M, Trépo C, Agathon D, Toh ML, Baudin M, Bonnefoy JY, Limacher JM, Inchauspé G.

Gastroenterology. 2011 Sep;141(3):890-899.e1-4. doi: 10.1053/j.gastro.2011.06.009. Epub 2011 Jun 13.

PMID:
21699798
15.

Single lysophosphatidylcholine components exhibit adjuvant activities in vitro and in vivo.

Bach G, Perrin-Cocon L, Gerossier E, Guironnet-Paquet A, Lotteau V, Inchauspé G, Fournillier A.

Clin Vaccine Immunol. 2010 Mar;17(3):429-38. doi: 10.1128/CVI.00420-09. Epub 2010 Jan 13.

16.

Vaccination against hepatitis B and C: towards therapeutic application.

Inchauspe G, Bach G, Martin P, Bonnefoy JY.

Int Rev Immunol. 2009;28(1):7-19. doi: 10.1080/08830180802488436. Review. No abstract available.

PMID:
19241251
17.

Hepatitis C vaccine: supply and demand.

Inchauspé G, Honnet G, Bonnefoy JY, Nicosia A, Strickland GT.

Lancet Infect Dis. 2008 Dec;8(12):739-40. doi: 10.1016/S1473-3099(08)70266-4. No abstract available.

PMID:
19022189
18.

A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus.

Martin P, Simon B, Lone YC, Chatel L, Barry R, Inchauspé G, Fournillier A.

Vaccine. 2008 May 12;26(20):2471-81. doi: 10.1016/j.vaccine.2008.03.028. Epub 2008 Apr 1.

PMID:
18423948
19.

Vaccines and immunotherapies against hepatitis B and hepatitis C viruses.

Inchauspé G, Michel ML.

J Viral Hepat. 2007 Nov;14 Suppl 1:97-103. Review.

PMID:
17958650
20.

An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses.

Fournillier A, Gerossier E, Evlashev A, Schmitt D, Simon B, Chatel L, Martin P, Silvestre N, Balloul JM, Barry R, Inchauspé G.

Vaccine. 2007 Oct 16;25(42):7339-53. Epub 2007 Aug 31.

PMID:
17875349
21.

Expression of the alternative reading frame protein of Hepatitis C virus induces cytokines involved in hepatic injuries.

Fiorucci M, Boulant S, Fournillier A, Abraham JD, Lavergne JP, Paranhos-Baccala G, Inchauspé G, Bain C.

J Gen Virol. 2007 Apr;88(Pt 4):1149-62.

PMID:
17374758
22.

Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity.

Rollier CS, Paranhos-Baccala G, Verschoor EJ, Verstrepen BE, Drexhage JA, Fagrouch Z, Berland JL, Komurian-Pradel F, Duverger B, Himoudi N, Staib C, Meyr M, Whelan M, Whelan JA, Adams VC, Larrea E, Riezu JI, Lasarte JJ, Bartosch B, Cosset FL, Spaan WJ, Diepolder HM, Pape GR, Sutter G, Inchauspe G, Heeney JL.

Hepatology. 2007 Mar;45(3):602-13. Erratum in: Hepatology. 2007 Jun;45(6):1590. Adams, Victoria A [corrected to Adams, Victoria C]; Lasarte, Juan José [corrected to Lasarte, Juan J].

PMID:
17326154
23.

Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein.

Martin P, Parroche P, Pajot A, Chatel L, Barreto C, Touat L, Dubois V, Rohrlich PS, Bain C, Trépo C, Negro F, Inchauspé G, Fournillier A.

Microbes Infect. 2006 Aug;8(9-10):2432-41. Epub 2006 Jun 30.

PMID:
16859951
24.

HEP DART 2005 -- HCV therapeutics.

Inchauspe G.

IDrugs. 2006 Mar;9(3):168-70. No abstract available.

PMID:
16523377
25.

Primary and memory T cell responses induced by hepatitis C virus multiepitope long peptides.

Fournillier A, Dupeyrot P, Martin P, Parroche P, Pajot A, Chatel L, Fatmi A, Gerossier E, Bain C, Lone YC, Trépo C, Inchauspé G.

Vaccine. 2006 Apr 12;24(16):3153-64. Epub 2006 Jan 31.

PMID:
16481078
26.

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.

Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A.

Hepatology. 2005 Oct;42(4):962-73. Review.

PMID:
16149085
27.

Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.

Rollier C, Verschoor EJ, Paranhos-Baccala G, Drexhage JA, Verstrepen BE, Berland JL, Himoudi N, Barnfield C, Liljestrom P, Lasarte JJ, Ruiz J, Inchauspe G, Heeney JL.

J Infect Dis. 2005 Sep 1;192(5):920-9. Epub 2005 Aug 1.

PMID:
16088843
28.

First Dominique Dormont International Conference on "Host-pathogen interactions in chronic infections - viral and host determinants of HCV, HCMV, and HIV infections".

Menu E, Müller-Trutwin MC, Pancino G, Saez-Cirion A, Bain C, Inchauspé G, Gras GS, Mabondzo AM, Samri A, Boutboul F, Le Grand R.

Retrovirology. 2005 Apr 6;2:24.

29.

Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC).

Nattermann J, Schneiders AM, Leifeld L, Langhans B, Schulz M, Inchauspé G, Matz B, Brackmann HH, Houghton M, Sauerbruch T, Spengler U.

J Hepatol. 2005 Apr;42(4):499-504. Epub 2005 Jan 21.

PMID:
15763336
30.

Effect of the 5' non-translated region on self-assembly of hepatitis C virus genotype 1a structural proteins produced in insect cells.

Girard C, Ravallec M, Mariller M, Bossy JP, Cahour A, López-Ferber M, Devauchelle G, Inchauspé G, Duonor-Cérutti M.

J Gen Virol. 2004 Dec;85(Pt 12):3659-70.

PMID:
15557239
31.

Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen.

Martin P, Parroche P, Chatel L, Barretto C, Beck A, Trépo C, Bain C, Lone YC, Inchauspé G, Fournillier A.

J Med Virol. 2004 Nov;74(3):397-405.

PMID:
15368525
32.

Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection.

Bain C, Parroche P, Lavergne JP, Duverger B, Vieux C, Dubois V, Komurian-Pradel F, Trépo C, Gebuhrer L, Paranhos-Baccala G, Penin F, Inchauspé G.

J Virol. 2004 Oct;78(19):10460-9.

33.

Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins.

Abraham JD, Himoudi N, Kien F, Berland JL, Codran A, Bartosch B, Baumert T, Paranhos-Baccala G, Schuster C, Inchauspé G, Kieny MP.

Vaccine. 2004 Sep 28;22(29-30):3917-28.

PMID:
15364440
34.

Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.

Steinmann D, Barth H, Gissler B, Schürmann P, Adah MI, Gerlach JT, Pape GR, Depla E, Jacobs D, Maertens G, Patel AH, Inchauspé G, Liang TJ, Blum HE, Baumert TF.

J Virol. 2004 Sep;78(17):9030-40.

35.

Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection.

Goutagny N, Vieux C, Decullier E, Ligeoix B, Epstein A, Trepo C, Couzigou P, Inchauspe G, Bain C.

J Infect Dis. 2004 May 1;189(9):1646-55. Epub 2004 Apr 15.

PMID:
15116301
36.

Analysis of B-lymphocyte differentiation in patients infected with hepatitis C virus.

Fournillier A, Freida D, Defrance T, Merle P, Trépo C, Inchauspé G.

J Med Virol. 2004 Apr;72(4):566-74.

PMID:
14981759
37.

Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response.

Rollier C, Depla E, Drexhage JA, Verschoor EJ, Verstrepen BE, Fatmi A, Brinster C, Fournillier A, Whelan JA, Whelan M, Jacobs D, Maertens G, Inchauspé G, Heeney JL.

J Virol. 2004 Jan;78(1):187-96.

38.

Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection.

Goutagny N, Fatmi A, De Ledinghen V, Penin F, Couzigou P, Inchauspé G, Bain C.

J Infect Dis. 2003 Jun 15;187(12):1951-8. Epub 2003 May 29.

PMID:
12792872
39.

Development of a hepatitis C virus vaccine.

Inchauspé G, Feinstone S.

Clin Liver Dis. 2003 Feb;7(1):243-59, xi. Review.

PMID:
12691469
40.

Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection.

Himoudi N, Abraham JD, Fournillier A, Lone YC, Joubert A, Op De Beeck A, Freida D, Lemonnier F, Kieny MP, Inchauspé G.

J Virol. 2002 Dec;76(24):12735-46.

41.

Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells.

Laporte J, Bain C, Maurel P, Inchauspe G, Agut H, Cahour A.

Blood. 2003 Jan 1;101(1):52-7. Epub 2002 Jun 28.

42.

Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles.

Brinster C, Chen M, Boucreux D, Paranhos-Baccala G, Liljeström P, Lemmonier F, Inchauspé G.

J Gen Virol. 2002 Feb;83(Pt 2):369-81.

PMID:
11807230
43.

[Role of neutralizing antibodies and cellular immunity in hepatitis C virus infection].

Inchauspé G.

Transfus Clin Biol. 2001 Dec;8(6):471-4. Review. French.

PMID:
11802609
44.

Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope.

Brinster C, Muguet S, Lone YC, Boucreux D, Renard N, Fournillier A, Lemonnier F, Inchauspé G.

Hepatology. 2001 Dec;34(6):1206-17.

PMID:
11732011
45.

Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites.

Fournillier A, Wychowski C, Boucreux D, Baumert TF, Meunier JC, Jacobs D, Muguet S, Depla E, Inchauspé G.

J Virol. 2001 Dec;75(24):12088-97.

46.

Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C.

Düesberg U, Schneiders AM, Flieger D, Inchauspé G, Sauerbruch T, Spengler U.

J Hepatol. 2001 Nov;35(5):650-7.

PMID:
11690712
47.

DNA vaccines for hepatitis C virus.

Brinster C, Inchauspé G.

Intervirology. 2001;44(2-3):143-53. Review.

PMID:
11509875
48.

[Dendritic cells and hepatitis C virus].

Bain C, Inchauspé G.

Pathol Biol (Paris). 2001 Jul;49(6):464-5. French.

PMID:
11484605
49.

Lipidation of T helper sequences from hepatitis C virus core significantly enhances T-cell activity in vitro.

Langhans B, Braunschweiger I, Schweitzer S, Jung G, Inchauspé G, Sauerbruch T, Spengler U.

Immunology. 2001 Apr;102(4):460-5.

50.

Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection.

Bain C, Fatmi A, Zoulim F, Zarski JP, Trépo C, Inchauspé G.

Gastroenterology. 2001 Feb;120(2):512-24.

PMID:
11159892

Supplemental Content

Loading ...
Support Center